AM IndustryAM Press ReleasesBioprintingDistribution

Ourobionics becomes a distribution partner for Humabiologics in Europe

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Ourobionics entered into a non-exclusive agreement with Humabiologics, a US biotech company specializing in the development and commercialization of human biomaterials for regenerative medicine research applications. The partnership agreement allows Humabiologics to respond to the growing demand and serve a broader life sciences customer base of industry partners and academic institutions in the European market. Under this agreement, European customers will have quick and convenient access to Humabiologics products through Ourobionics. By sharing the similar vision to empower research and making biofabrication processes more accessible, Ourobionics and Humabiologics will set a new standard to position themselves as industry leaders of advanced tissue engineering and regenerative therapies.

Humabiologics biomaterials The use of animal products in research can lead to poor translation aspects, irrelevant outcomes, and regulatory hurdles that can slow the development of life science innovations. Humabiologics human-derived products are designed to address these challenges by offering high quality, supply-stable, and affordable native human-derived biomaterials for translational regenerative medicine therapies such as cell therapy, bioprinting, tissue & disease modeling, or drug screening. Humabiologics developed proprietary processes based on tissue industry quality system standards to manufacture its products and only partners with FDA-registered and accredited tissue banks around the US to utilize thoroughly screened donated human tissue that will not be used for transplant. Humabiologics product offerings are unique and include the most affordable native human skin collagen, first human bone gelatin, and native human extracellular matrix that can be used similarly to Matrigel, with more products being developed and will be launched soon based on market demand.

By developing and supplying up-to-date, cutting-edge technologies in biofabrication and tissue engineering, Ourobionics wants to offer complete, standardized processes to its customers and make the field of biofabrication more accessible to any professional with a vision and a purpose. Moreover, increasing the number of advanced technologies available for commercial use will set a new quality benchmark of biofabricated products (such as 3D cell cultures, organoids or ready-to-use tissue models) and unlock new, more complex applications. This shift is expected to help drive $40B global regenerative medicine market in the next 5 years.

Ourobionics and Humabiologics share the awareness of how precious the gift of life is and understand the value of extending the gift of donation. By joining forces, and offering unique and more clinically relevant products, both companies will actively pursue the mission to help as many people as possible.

Composites AM 2024

746 composites AM companies individually surveyed and studied. Core composites AM market generated over $785 million in 2023. Market expected to grow to $7.8 billion by 2033 at 25.8% CAGR. This new...

Victor Anusci

Victor does not really exist. He is a pseudonym for several writers in the 3D Printing Media Network team. As a pseudonym, Victor has also had a fascinating made-up life story, living as a digital (and virtual) nomad to cover the global AM industry. He has always worked extra-hard whenever he was needed to create unique content. However, lately, as our editorial team has grown, he is mostly taking care of publishing press releases.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services


Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.